Researchers at Chalmers University of Technology, Sweden, have succeeded in developing a method to label mRNA molecules, and thereby follow, in real time, their path through cells, using a microscope – without affecting their properties or subsequent activity. The breakthrough could be of great importance in facilitating the development of new RNA-based medicines.
CLSI publishes new document C64 – Quantitative Measurement of Proteins and Peptides by Mass Spectrometry, 1st edition
The Oxford, UK-based Orbit Discovery, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has raised US$7.6 million in funding.
Eli Lilly and Company and their industry partners, including sample management specialists – Ziath, are speeding the discovery of new medicines through the fully automated Lilly Life Sciences Studio (L2S2) lab in San Diego, USA
Porvair Sciences has installed new automated precision die-cutting equipment that has enabled a five-fold increase in its production capacity for porous plastic components.
A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, has launched Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the Global […]
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures singleand multi-organ microphysiological systems (MPS), has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
Biotium, a leading provider of reagents for immunofluorescence microscopy, is significantly expanding its line of antifade wet-set and hardset EverBrite Mounting
German independent research institute BioMed X has started two new research projects with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.